Introduction
One of the key signal transduction pathways involved in malign transformation is the PTEN/PI3K/AKT pathway which regulates cellular metabolism, cell growth, translation, chromosome stability and cell survival [1] . PTEN (Phosphatase and tensin homolog deleted on chromosome ten) is a lipid and dual function phosphatase that antagonizes the PI3K/AKT pathway, through dephosphorylates the PI3K (Phosphoinositide 3-kinase) produces PIP2 (Phosphatidylinositol 4,5-bisphosphate) and PIP3 (Phosphatidylinositol (3, 4, 5) -triphosphate) so that terminates transmitting of the signal to AKT and other PIP3-effector targets [2] . AKT1 is a serin threonine kinase that modulates the cell cycle checkpoint [3] . AKT1 is activated by platelet-derived growth factor and its activation is deregulated by mutations in the pleckstrin homology domain of AKT1. Survival factors can suppress apoptosis in a transcription-independent manner by activating the serine/threonine kinase AKT1, which then phosphorylates and inactivates components of the apoptotic machinery [4] . PTEN as a tumor suppressor is frequently mutated in cancers and its inactivation results in constitutive activation of the PI3K/AKT pathway. PTEN is a regulatory key to prevent the malignant transformation of T-cells [5] . The PTEN/AKT pathway has an important role in β-selection checkpoint in T cell development and lymphocyte homeostasis [6] . PTEN deficient T cells are found highly proliferative as a cause of increased phosphorylation of AKT [7] . AKT1 is highly expressed in thymus tissue and knockout studies showed that terminal differentiation in CD8+ T cells was failed so that increased proliferation, cytokine secretion and prolonged survival [8, 9] . PTEN/AKT abnormalities resulting in deletion, insertion or missense mutations lead to differential regulation in different hematologic malignancies [10] [11] [12] [13] [14] . Genomic re-sequencing results showed that PI3K/AKT pathway genes are commonly mutated in pediatric and young adult T-ALL cases [11, 15] . In this study, PTEN and AKT1 variations and their clinical associations were analyzed in a group of childhood T-ALL cases.
Materials and Methods
Childhood T-ALL cases (n=50) who were diagnosed at Istanbul University Faculty of Medicine and Cerrahpasa University Faculty of Medicine were included in this study. The cases were treated according to the BFM (Berlin-Frankfurt-Munster)-ALL protocol. Diagnostic bone marrow (BM) samples with a blast count of >80% were included in the study. The T cell origin of ALL was defined by expression of immunophenotype markers that included CD1a, CD2, cytoplasmic CD3, surface CD3, CD4, CD5, CD7, CD8. T-ALL cases were evaluated according to the EGIL (European Group for the Immunological Characterization of Leukemia) classification scale as immature (n=20), cortical (n=17), or mature (n=4), however nine cases were not be able to further classified due to limited immunological marker information [11] . Median age was 8 (min 0.9-max 17) years old and other clinical features of the T-ALL cases are summarized in Table 1 . Written and oral informed consents were obtained from legal representatives of the pediatric cases.
Identification of PTEN and AKT1 variations
The mononuclear cells of case's bone marrow samples were isolated by the ficoll density gradient procedure [16] . Genomic DNA was isolated by QIAamp DNA Mini Kit (Qiagen GmbH, Hilden, Germany) according to the manufacturers' protocol. DNA quality and quantity were checked by a spectrophotometer (Nanodrop 100, Thermo scientific, USA). The hotspot regions of PTEN (exons 7 and 8) and AKT1 (exon 2) were covered by primer pairs, which were designed and validated by the ALL package of the IRON-II (Interlaboratory RObustness of Next-Generation Sequencing) phase study ( Roche FLX GS Junior (454-Life Sciences, Branford, CT) according to the manufacturer's instructions. The minimum read depth threshold per amplicon, per sample was set to 500x. Sanger sequencing was used to confirm the variations, and low-level variants (variant calling was <20%) were re-sequenced by using a different MID. After the data quality assessment, variant detection analyses were done by AVA software (GS Amplicon Variant Analyzer software version 2.5.3-Roche Applied Science). In silico prediction tools, Mutation taster [17] , SIFT [18] were used to evaluate the functional effects of identified variants in PTEN (NM_000314.4) and AKT1 (NM_005163.2).
Results
A total of 50 childhood T-ALL patients were screened for hotspot regions of PTEN and AKT1 by targeted deep sequencing. All the detected variations are listed in Table 3 . A total of five PTEN variations were found in three of the 50 T-ALL cases (6%) and all the variations occurred in exon 7, truncating PTEN in the C2-domain. A nonsense c.781C>T, p.Q261* (rs730882131) pathogenic variant was found in a patient (P#7) with a low frequency (2.1%) and this somatic variation was evaluated as a small background clone without any clinical significance. P#7 is a 3.5 years old boy who is classified in the medium risk group (MRG), responder to induction therapy and followed by 27 months. Three novel variants including insertions and deletions were detected in two T-ALL cases. The patient (P#48) had two different mutant clones for PTEN; the first clone carried c.700_701insCTGGAGCCGAC p.R234Pfs*26 with 40% frequency and the second clone harbored c.707_720delACAAGTTCATGTAC and c.724_740delGAGTTCCCTCAGCCGTT deletions that cause p.D236Vfs*6 with 16% frequency which are classified as "deleterious" by SIFT. The deletion area was able to detected by conventional sequencing however, it was not possible to distinguish the clones ( Figure 1B ). P#48 is a 12 years old girl that had high white blood cell count at diagnosis (170X10 9 /L) with lymphadenopathy, splenomegaly and hepatomegaly, responder to induction therapy and have been followed in remission for 90 months. The patient (P#27) was also had two variations on the PTEN gene; a likely pathogenic deletion c.703delG, p.G235Kfs*21 with a 10% frequency and a novel insertion c.737_738insAAG, p.P246_L247insR with 4.6% frequency ( Figure 1A ). She is seven years old who is classified in the MRG and responder to induction therapy. She was presented with lymphadenopathy, splenomegaly, hepatomegaly and mediastinum involvements. She had early relapse and still under remission for 80 months. Furthermore, two common intronic single nucleotide variations (SNVs), rs2494749 (8%) and rs2494748 (6%) were found in the AKT1 gene. However, none of the cases carried the diseased linked variation in exon 2 of the AKT1 gene. NOTCH1/FBXW7 mutation data were available for 24 of the patients [19] . None of the patients who had NOTCH1/FBXW7 variations carried PTEN or AKT1 mutation for the respective exons. Also, patients who had PTEN or AKT1 variation were not carried t(9;22), t(12;21), t(4;11). Discussion PTEN has an important role in the proliferation and survival of T-cell progenitors, and its loss may sustain leukemic T-cell viability in T-ALL [20] . PTEN function is often inactivated by different mechanisms such as mutations, epigenetic alterations, gene silencing and post-translational modifications in cancers where it can be associated with reduced chemotherapy response and poor prognosis [21, 22] . The frequency of the PTEN variation was previously reported as 5-27% in different studies in T-ALL patients. Different methodologies, number of analyzed cases, whole exome or hot spot regions examination may explain this diversity. In our study, exon 7 and exon 8, which are the hot regions for the PTEN gene variations were screened with targeted amplicon sequencing. Three patients had PTEN mutations in our cohort, on the other hand two of the patients harbored multiple PTEN mutant clones that we were able to distinguish by deep sequencing. Furthermore, two patients showed low-level PTEN variations; we may consider that PTEN mutations were not the first to be hit for the oncogenic behavior in these T-ALL patients. In common with the other studies, all the mutations were cumulated in exon 7 and two novel frame shift mutations were detected in one patient and were predicted to cause truncated protein. Truncating mutations located within the first eight exons of the PTEN gene lead to mono allelic expression by nonsense mediated decay [23] . Furthermore, nonsense PTEN variation was found in a T-ALL patient that resulted in the loss of PTEN protein levels [10] . All the mutant patients for PTEN were achieved remission after the induction therapy and one patient was developed early relapse. Furthermore, all patients were alive during the follow up. PTEN is implicated in regulating downstream effects of NOTCH1 signaling such as proliferation and survival of T-cell progenitors. Also, PTEN mutations were suggested to be secondary mutations following NOTCH1-activating mutations, rendering cells insensitive to γ-secretase inhibitors. On the other hand, other studies suggested that NOTCH1activating mutations and PTEN mutations were two different hits in different T-ALL subgroups [21, 24] .
Especially PTEN mutant patients associated with TAL-1 expressed group in T-ALL. In our cohort, 30% of T-ALL patients harbored NOTCH1/FBXW7 mutations and none of the PTEN mutant samples carried NOTCH1/FBXW7 aberrations [19] . Previous studies have reported the controversial prognostic effects of PTEN variations in childhood T-ALL [11, 13, 25] . In the BFM (n=301) and GBTL1 ALL-99 (Brazilian) (n=62) pediatric ALL cohort studies showed u n c o r r e c t e d p r o o f that in the absence of NOTCH1 mutations PTEN gene variations were associated with poor prognosis, DCOG/COALL (German) (n=146) cohort study reported PTEN variations as independent high risk factor for relapse [10] , where as UKALL2003 (n=145) pediatric cohort could not find any association between PTEN variations and clinical findings [11] . Italian study group were examined 257 children with T-ALL treated with AIEOP-BFM protocols. They found an association between increased risk of relapse and PTEN mutations in pediatric T-ALL [26] . In other study, Szarzynska-Zawadzka et al. screened 162 patients with T-ALL for PTEN aberrations (mutations, copy number variations and deletions) and found PTEN deletions were more common than mutations (16% vs 9%) in patients. Beside that, bi-allelic inactivation of PTEN (co-occurrence of deletions and mutations) was detected in 8% of patients. PTEN deletions were associated with worse survival and increased risk of relapse. However, PTEN mutations were associated with poor survival but not with relapse [27] . These findings suggest the existence of multiple leukemic sub-clones displaying various PTEN anomalies, with each of these subsets possibly having different biological and clinical features. Detailed analysis of the type of genetic anomaly would be useful to refine risk stratification based on PTEN status.
Study Limitations
The study has some limitations. The number of patients in the study is limited and the patients had only been screened for the hot spot regions of the genes although variation frequencies are similar to the other studies. Conclusion PTEN tumour suppressor gene inactivation is a frequent event in T-ALL but its effect on patient therapy response is debatable. Herein, only a small proportion of T-ALL patients had PTEN and AKT1 variations. Therefore, it is not possible to reach a meaningful conclusion about prognostic value of PTEN mutations in T-ALL. In our cohort, screening for PTEN abnormalities at diagnosis did not add further information to patients risk groups. However, PTEN genotype may serve as a potential biomarker for targeted therapy in later perspective studies. Beside that, PTEN mutations are not the only aberration that contributes to the loss of PTEN protein in T-ALL patient samples. Other PTEN aberrations (copy number variations, deletions), different molecular mechanisms like effective PTEN-splicing, long noncoding RNAs, epigenetic modulations that are also leading PTEN inactivation should also be evaluated in the future. The PTEN/AKT pathway has a critical role in cell growth and survival and has become a target pathway for pharmacological studies due to its frequent activation in various types of tumors [28] [29] [30] [31] [32] . In order to identify patients who may benefit from novel developed therapeutics, it is important to characterize the molecular background of the patients.
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